Stockreport

MoonLake Immunotherapeutics: Novel Technology, But Still In Phase 3 [Seeking Alpha]

MoonLake Immunotherapeutics - Class A Ordinary Shares  (MLTX) 
PDF The company is focusing on psoriasis and hidradenitis suppurativa, targeting interleukins 17A and 17F as the main culprits for excessive inflammation. MoonLake has co [Read more]